IMAGE

Fig. S12

ID
ZDB-IMAGE-190826-4
Source
Figures for Whitesell et al., 2019
Image
Figure Caption

Fig. S12

Treatment of Metronidazole (MTZ) does not affect vessel patterning or vSMC coverage along the ventral aorta in embryos.  A-C) 4 dpf acta2:EGFP, kdrl:mCherry E3 control embryos lacking the NTR construct (A) show that treatment with MTZ does not affect vascular patterning or development of vSMC when using the same doses for acta2:Gal4 (B) or foxc1b:Gal4 (C) ablation. n = 4 embryos per panel. D) Quantification of vSMC coverage from data in Figure 9 A-D, using live transgenics (foxc1b:Gal4; UAS-NTR:mCherry or acta2:Gal4; UAS-NTR:mCherry) at 4 dpf. E) Quantification of vSMC coverage in Figure 9 E-H, using acta2 mRNA in situ hybridization. F)  Quantification of vSMC coverage using live transgenics lacking NTR construct (acta2:EGFP, kdrl:mCherry). Data points in D-F represent individual embryos. *** = p < 0.001, ANOVA with Sidak’s multiple comparisons test. Scale bar represents 50 µm.

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image.

Reprinted from Developmental Biology, 453(1), Whitesell, T.R., Chrystal, P.W., Ryu, J.R., Munsie, N., Grosse, A., French, C.R., Workentine, M.L., Li, R., Zhu, L.J., Waskiewicz, A., Lehmann, O.J., Lawson, N.D., Childs, S.J., foxc1 is required for embryonic head vascular smooth muscle differentiation in zebrafish, 34-47, Copyright (2019) with permission from Elsevier. Full text @ Dev. Biol.